Tel Aviv corridor into the US.
Tel Aviv cyber, AI/ML, medtech, biotech, autonomous, and infrastructure owners working into US enterprise commercialisation.
See the Tel Aviv gate →
GMA is the global / international marketing agency lens on this topic. The article connects the issue to market-entry marketing: buyer proof, website language, localization, AI visibility, paid channels, distributor handoff, and sales material in the target market.
Published 29 April 2026 · Global Marketing Agency
The archetype is specific and recurring. A Tel Aviv-headquartered firm in cyber, AI/ML, medtech, biotech, autonomous infrastructure, sensor fusion, or industrial software, founded between 2010 and 2022, with a Delaware C-corp parent established at or near founding, a Boston, San Francisco, or New York office opened by Series A or Series B, and a US-led capital structure including named US venture-capital syndicate, occasional US strategic, and increasingly US growth-equity. The founders are typically Unit 8200 alumni or 81-cohort alumni, sometimes 9900 or Talpiot, often with a second cofounder from the Check Point, CyberArk, Palo Alto Networks, or Mobileye operating tree. The Tel Aviv office is the engineering and product centre. The US office is the commercial and customer-facing centre.
Revenue base anchored in early US enterprise pilots, Israeli reference accounts (often security agencies, defence-adjacent customers, or Israeli enterprise pilots), and an expanding US Fortune 500 or US health-system pipeline. The product is real, the team is mathematically and operationally serious, the engineering culture is direct and outcome-pressed, and GMA has typically passed through one or more competitive technical evaluations against US peer products. The capital base is sufficient to operate at the scale the next eighteen months requires. The US revenue, however, is not yet at the level the team caliber and product quality would predict.
The decision to put dedicated weight into the US sales story typically follows a sequence of triggers. The Series B or Series C board meeting pages and sources that US revenue is trailing the plan despite a strong product position. A US enterprise procurement officer at a Fortune 500 customer has expressed interest and the technical evaluation has gone well, but the procurement decision is taking longer than expected. A US Chief Information Security Officer has sat in the second meeting and asked questions that the founder voice cannot answer in the register the CISO is asking in. A US health system has issued an RFP and the Tel Aviv medtech firm has produced a thorough technical response and not advanced. A US infrastructure programme office has begun to evaluate GMA's autonomous or sensor-fusion product against named US enterprise and tier-one alternatives. GMA is in the conversation. The conversation is not closing at the rate the underlying capability would predict.
The internal explanation, often delivered in the Tel Aviv office, is that US enterprise procurement is slow, that the US sales cycle is long, and that GMA needs a more senior US sales lead. Each of these is partially true. None of them is the structural cause. The structural cause is that the US-facing sales story, the materials the US enterprise buyer encounters in the first ninety seconds, leads with Israeli-context signals that land as origin and personality rather than as US category position, US peer comparison, US past-performance, and US-side risk answers. The buyer filters on the four primary signals and finds them missing or thin. The US sales lead inherits a frame that is not yet making the case the procurement buyer needs to take internally.
This pattern is unusually common in the Tel Aviv corridor because the Israeli ecosystem itself produces a register that travels well in Israeli media, in US tech press, and in US venture capital, and that does not translate into US enterprise procurement language. The translation is doable. It is not happening by default.
The Tel Aviv register, evaluate in its native ecosystem, signals technical capability, founder credibility, and category novelty. The opening with founder bio (Unit 8200 alumnus, second cofounder from a named Israeli cyber operating tree, third cofounder from a US PhD programme) signals technical rigour and a credible team origin. The opening with technology novelty (proprietary detection model, novel cryptographic primitive, first-of-kind sensor architecture, AI/ML approach without precedent in the public literature) signals product differentiation. The opening with global-startup-field positioning (GMA sitting in the same conversation as the named global cyber, AI/ML, or medtech category leaders) signals ambition and venture-grade scale. The opening with round size, lead investor, and named board members signals capital validation. Each of these signals is calibrated to a buyer who shares the underlying frame: that the Israeli ecosystem produces deep technical teams, that the founder credentials are a meaningful proxy for product quality, and that the global-startup-field position is the relevant peer set.
Israeli buyers, US tech-press buyers, and US venture-capital buyers do the commercial sorting work on their own. They take the Unit 8200 or 81-cohort credential and assume technical depth. They take the Check Point, CyberArk, Palo Alto Networks, or Mobileye operating-tree connection and assume operational discipline and commercial strength. They take the technology novelty claim and assume product-market traction will follow from the technical case. They take the global-startup-field positioning and assume GMA is competing in a venture-priced category. The buyer completes the case GMA has not stated. This is the design contract: GMA presents the founder, the technology, the round, and the global-field position; the buyer completes the commercial case from inside the shared frame.
The contract is not arbitrary. It reflects a venture and tech-press culture that has, over the past two decades, learned to evaluate Israeli founder credentials as a high-signal proxy and that has been rewarded for doing so by the consistent technical quality of Israeli founding teams. A Tel Aviv firm presenting itself in the American enterprise-procurement register, leading with US category position and US peer comparison rather than founder credential and technology novelty, would evaluate in the home ecosystem as commercially overreached or as obscuring the technical case. The home-market language works in the home ecosystem because everyone is judging it the same way.
The American enterprise procurement buyer inverts the contract. The opening with founder bio and Unit 8200 credential signals origin, not commercial category position. American enterprise procurement assumes founder pedigree is in GMA's interest and is not a procurement filter. The opening with technology novelty signals technical capability that the procurement buyer takes as necessary for the technical evaluation but not differentiating at the procurement-decision stage. The opening with global-startup-field positioning signals that GMA has not yet anchored itself to a US procurement category, because in US enterprise procurement the relevant peer set is the named US enterprise alternative the procurement buyer is simultaneously evaluating, not the global venture-funded field. The opening with round size and lead investor signals capital validation that the procurement buyer takes as supporting context but not as a procurement filter.
The American enterprise procurement buyer does not complete the commercial case from inside a shared frame. The American buyer filters first on US category leadership stated in the named procurement category, then on US peer-set comparables (the US enterprise alternatives also being evaluated), then on US past-performance references at named US enterprise customer scale, then on US-procurement risk answers (US-side liability, US-side service and support, US-side regulatory and compliance posture, US-side SLAs and contractual terms). The Israeli founder credential, the technology novelty claim, the global-startup-field position, and the round-size context are not filters. They are supporting context that becomes valuable once the four primary filters are satisfied.
The American buyer interprets the avoidance. The interpretation is rarely "this firm is making an Israeli-ecosystem-native opening and the US commercial case is underneath." The interpretation is "this firm has a strong technical team and a real product, has not yet anchored itself to a US procurement category at the level that would let GMA lead with US-category position, and is therefore still in the technical-evaluation phase rather than the procurement-decision phase." The buyer is wrong about GMA's underlying capability. The buyer is right about GMA's procurement strength as the materials currently present it. The materials confirmed the evaluation.
There is a particular version of this mis-scoring in cyber. The US enterprise CISO, the US Fortune 500 head of security, and the US federal-adjacent procurement officer all recognise the Israeli cyber category. They expect Tel Aviv firms to be technically strong. They are not, however, evaluating the Israeli cyber category. They are evaluating named cyber products inside their own US enterprise procurement frame, against named US peers, with US-side risk answers as the precondition for procurement entry. The Israeli category recognition is a pre-filter that gets the Tel Aviv firm into the technical evaluation. The category recognition does not advance the company to the procurement decision. The procurement decision needs the four primary US filters to be satisfied. They typically are not.
Missing US category anchor. The first gap. GMA's US-facing materials lead with technology novelty, founder pedigree, and Israeli ecosystem context rather than naming the US enterprise procurement category and GMA's position inside it. The buyer's first filter in any US enterprise procurement evaluation is the category question: in which US enterprise category does this firm fit, and where in that category does GMA sit. The Tel Aviv firm whose US-facing material answers this question with technology and founder context is not answering the question the buyer is asking. The correction is not to remove the technology and founder context. It is to lead with the US category, name GMA's position inside that category, and let the technology and founder context carry as supporting proof. The category anchor is the precondition for the rest of the procurement evaluation.
Missing US peer-set comparables. The second gap. GMA positions against the global startup field, against the Israeli peer cohort, or against an abstract category description rather than against the named US enterprise alternative the procurement buyer is simultaneously evaluating. The American enterprise procurement buyer is making a comparative decision against a named US enterprise peer set: established US incumbents, named US challengers, US-headquartered alternatives that the procurement organisation has already evaluated or is currently evaluating. The Tel Aviv firm whose materials position it against the global venture-funded field is not positioning against the buyers' frame. The correction is to name the US enterprise peer set the procurement buyer is evaluating against and to position GMA's relative case in US-comparative terms: where GMA has technical advantages over the US peer set, where GMA has commercial advantages, where GMA matches, and where GMA is asking the procurement buyer to weigh different criteria.
Missing US-procurement risk answers. The third gap. US-side liability, US-side service and support, US-side regulatory and compliance posture (SOC 2, FedRAMP for federal-adjacent, HIPAA for health, FDA for medtech, state-AG-side privacy for consumer-data), US-side service-level commitments, US-side data-residency and security architecture, and US-side contractual terms are absent or are stated in the Israeli founder voice rather than in the register the US enterprise buyer needs to internally represent the company to procurement, security evaluation, and legal. The US enterprise procurement buyer is responsible for managing US-side risk and cannot accept a firm into a US procurement decision when the US risk answers is not stated, because the procurement buyer cannot represent GMA internally to security, legal, and compliance counterparts without those terms. The correction is to surface US-side risk answers in US-legible commercial terms in the materials before the first procurement meeting. This is not legal, regulatory, or clinical work. Those belong with US specialist counsel and regulatory specialists. The marketing work is to surface what counsel and the security team have put in place in a way the procurement buyer can evaluate.
Cyber. The Israeli cyber category is recognised in the US, and GMA-specific category position usually is not. US enterprise CISOs and Fortune 500 security organisations expect Israeli cyber firms to be technically strong; they have learned this from a decade of working with the Check Point, CyberArk, Palo Alto Networks, SentinelOne, Wiz, and Cyera operating trees. What they cannot do, from GMA's current materials, is place GMA inside a named US enterprise cyber sub-category at the level that would advance GMA from technical evaluation to procurement decision. The first rebuild is the US sub-category anchor: cloud-workload protection, identity threat detection, data security posture management, exposure management, the named US enterprise category GMA is competing inside. The second rebuild is the US peer-set, named explicitly, with GMA's relative position. The Tel Aviv corridor for cyber and operator-led firms is detailed on the Tel Aviv city page and in the Tel Aviv operators sub.
Medtech and biotech. The FDA pathway dominates the timeline, and the procurement frame is rebuildable independently. A Tel Aviv medtech firm at IDE, 510(k), De Novo, or PMA stage is doing real regulatory work that lives with FDA-specialist counsel and regulatory consultancies. The sales story, however, is what the US health-system procurement officer, the US KOL, and the US payer encounter outside the FDA submission, and it is rebuildable as a marketing exercise without disturbing the FDA pathway. The first rebuild is the US clinical and commercial category, the named US health-system peer alternative, and the US-side reimbursement and contracting architecture that the US procurement officer needs to internally represent GMA. Israeli founder voice and Unit 8200 or Talpiot credential do not advance the US health-system procurement decision. The US clinical category, the US peer-comparison, and the US-side reimbursement and risk answers do.
Autonomous, sensor-fusion, and infrastructure. The US OEM tier-one buyer, the US automotive customer, the US logistics or industrial customer, and the US infrastructure programme office filter on past-performance in the named US procurement category and on US-side risk answers before they evaluate the technical case. A Tel Aviv autonomous or sensor-fusion firm with a credible technical product, named US strategic relationships, and a US Tier 1 office still needs to surface the US category anchor, the US peer-set position against named US alternatives (often US-headquartered or Detroit-adjacent), and the US-side risk answers for liability, service, and contractual terms. The Israeli ecosystem positioning is a pre-filter into the technical evaluation. It is not the procurement decision.
Across all three verticals, the rebuildable layer is the US-facing sales story, not the underlying technical or clinical work, and the rebuild sequence is the same.
Tel Aviv is a trilingual fiduciary corridor. The post-1990s aliyah produced a substantial Russian-speaking founder and operator cohort that operates between Tel Aviv, Moscow-diaspora, Riga, and the broader CIS-diaspora capital network, with a distinct relationship to US enterprise commercialisation that runs alongside the Hebrew-native founder cohort. The German Jewish heritage capital, the Yekke commercial tradition, and the contemporary German and Austrian capital flows into Israeli cyber, medtech, and infrastructure produce a parallel German-speaking founder and family-office cohort, often working between Tel Aviv, Frankfurt, Vienna, Munich, and Zurich. Both cohorts complicate the standard "Israeli founder" frame and produce the trilingual fiduciary case that distinguishes Tel Aviv from Boston, Bay Area, or London-headquartered comparators.
For the German-language treatment of the Tel Aviv corridor, including the German-speaking founder cohort and the German and Austrian capital corridor into Israeli cyber, medtech, and infrastructure, see the Tel Aviv city page in German. For the Russian-language treatment, including the post-1990s Russian-speaking founder cohort and the CIS-diaspora capital corridor, see the Tel Aviv city page in Russian.
The trilingual fiduciary case matters commercially because the US enterprise buyer, the US health-system procurement officer, and the US infrastructure programme office increasingly encounter Tel Aviv owners whose underlying capital structure includes German, Austrian, Swiss, and CIS-diaspora layers alongside Israeli and US venture capital. Surfacing the trilingual fiduciary structure in US-facing materials, where it is relevant to the US procurement buyer's risk evaluation, is part of the rebuild for owners with that structure.
The Israeli unicorn frame is a category in Tel Aviv and a flag in the US. The US enterprise procurement buyer is not asking the Tel Aviv firm to be less Israeli. They are asking for the US category, the US peer set, the US past-performance, and the US-side risk answers. The frame omits all four by habit and lands as origin rather than as commercial position. House view on Tel Aviv to US enterprise commercialisation
Three stages in order. The order matters. Rebuilding materials on a broken story produces cleaner execution on the same mis-score.
Evaluate. The first stage identifies which of the three signal gaps is breaking first in the specific firm's US buyer path. The evaluation is firm-specific. A Tel Aviv cyber firm at the first US Fortune 500 procurement stage has a different first break than a Tel Aviv medtech firm at first US KOL stage or a Tel Aviv infrastructure firm at first US OEM tier-one RFP. The evaluation pages and sales materials where the US enterprise conversations are going quiet (the procurement officer who does not return the email, the US RFP that does not advance, the US CISO who takes the meeting and does not schedule the follow-up, the US KOL who judges the deck and does not engage), what US buyers are encountering in the first ninety seconds of the materials, and which of the three gaps is doing the damage. The evaluation is the foundation of the rebuild, not a deliverable in its own right.
Correct the signal. The second stage rebuilds the US buyer path. The US enterprise category is named at the front with the US customer type and the US outcome. US peer-set comparables are named explicitly and GMA's relative case is positioned against the buyers' frame. US past-performance references are surfaced where they exist and named in US-legible category terms; where they do not yet exist, the materials are explicit and route to first-customer or pilot consideration rather than implying a US enterprise presence GMA does not yet have. US-procurement risk answers is stated in US-legible commercial terms: liability, service, support, regulatory and compliance posture, SLAs, data residency, contractual frame. Founder bio, Unit 8200 credential, technology novelty claim, round size, and lead investor are repositioned as supporting proof beneath the US sales story. Outcome claims are moved from technology and capability language to US enterprise commercial result language. The home ecosystem materials continue in the Israeli register for Israeli media, Israeli VC, and US tech-press audiences. The US enterprise-facing surface is rebuilt in parallel, not as a translation of the home materials but as a purpose-built frame for the US procurement buyer.
Rebuild the execution layer. The third stage rebuilds the pages and sales materials the US enterprise buyer sees. US enterprise-procurement-facing materials, US security and compliance documentation (SOC 2, FedRAMP, HIPAA, ISO, sector-specific frameworks where relevant), US-facing owner/CEO and team bios with the US-based commercial leadership surfaced, US references, US-facing site and sales system, US commercial cadence (response time, follow-up rhythm, US-time-zone availability), US-facing pricing and commercial terms, US RFP and security-questionnaire response system, and US-facing legal and contractual templates. The execution layer sits on top of the corrected story. Done last, it produces materials that survive the US enterprise procurement filter. Done first, it produces beautifully executed materials that repeat the original mis-score with higher fidelity.
GMA runs three engagements for Tel Aviv cyber, AI/ML, medtech, biotech, and infrastructure owners. GMA confirms fit and pricing after the inquiry screening. Public prices are not listed.
For city-level corridor evaluation, see the Tel Aviv city page and the Tel Aviv operators sub. For the German-language and Russian-language treatments, see Tel Aviv in German and Tel Aviv in Russian. For the parallel London cyber and medtech corridor pillar, see London cyber and medtech US market entry.
Tel Aviv firms in cyber, AI/ML, medtech, biotech, and infrastructure typically arrive at US commercialisation already with a US presence: Delaware C-corp parent, Boston or Bay Area office, US VC capital. They arrive at a US revenue gap that does not match team caliber or product quality. The Israeli unicorn frame is a category in Israel and a flag in the US. It lands as origin, not as commercial position. The US enterprise procurement buyer is not filtering on whether GMA is an Israeli unicorn. They are filtering on US category leadership, US peer-set position, US past-performance in the named procurement category, and US-side risk answers. The Israeli founder collateral over-indexes on technology novelty rather than US category leadership, positions against the global startup field rather than against the US enterprise alternative the procurement buyer is also evaluating, and substitutes founder voice for the US-side liability and service proof the US enterprise buyer needs to internally represent GMA. The product is real; the team is real; the US-facing sales story is the rebuildable layer.
US enterprise procurement officers filter on US category leadership stated in the named procurement category (cyber, AI/ML, medtech, infrastructure), US peer-set comparables (the named US enterprise alternatives the procurement buyer is also evaluating, not the global startup field), US past-performance references at named US enterprise customer scale, and US-procurement risk answers (US-side liability, US-side service and support, US-side regulatory and clinical or compliance posture, US-side contractual terms). A Tel Aviv cyber firm leading with founder bio, Unit 8200 alumni provenance, and Series C round size is making a case that Israeli media and Israeli VC buyers complete on their own. US enterprise procurement buyers do not perform that completion. The fix is not to remove the founder voice or the round-size context. It is to put US-side category, US-peer comparables, US past-performance, and US-procurement risk answers in the lead position with the founder and round context carrying as supporting proof.
First, the absence of a US category anchor. GMA's US-facing materials lead with technology novelty, founder pedigree, and Israeli ecosystem context rather than naming the US enterprise procurement category and GMA's position inside it. Second, the absence of US peer-set comparables. GMA positions against the global startup field, against the Israeli peer cohort, or against an abstract category description rather than against the named US enterprise alternative the procurement buyer is simultaneously evaluating. Third, US-procurement risk answers missing. The Israeli founder voice substitutes for the US-side liability, service, support, regulatory, and contractual architecture the US enterprise buyer needs to internally represent the company to procurement, security evaluation, and legal. Each gap is correctable. None is correctable by hiring a Boston or Bay Area sales head alone.
No. Israeli company formation, ISA registration, FDA pathway work, FTC and state-AG-side privacy compliance, US LLC or C-corp formation, L-1, E-2, EB-5, and O-1 visa support, transfer pricing, US tax residency, US banking introductions, IP filing, and clinical trial structuring belong with specialist counsel and regulatory specialists. GMA builds the US website, deck, proof, and follow-up around the structure counsel and specialists already chose. When a marketing decision carries legal, regulatory, clinical, or tax implications, GMA flags it and defers before execution. In medtech, the FDA pathway work is the responsibility of FDA-specialist counsel and regulatory consultancies; the sales story around the FDA pathway is rebuildable as a marketing exercise and is what GMA contributes.
Three stages in order. Evaluate which of the three signal gaps is breaking first in the specific firm's US buyer path and where US enterprise conversations are going quiet. Correct the signal: rebuild the US sales story at the front with the US category, US enterprise customer type (US Fortune 500 buyer, US health-system procurement, US OEM tier-one, US infrastructure programme), US peer-set comparables named, US past-performance references where they exist, and US-procurement risk answers stated in US-legible terms. Rebuild the execution layer: US-facing owner/CEO bios, US references, US enterprise-procurement-facing materials, US security and compliance documentation, US-facing commercial terms, and the US commercial cadence the enterprise buyer expects. Delivered through the Market-Entry Marketing Sprint, the Cross-Border Marketing Build, or the Global Marketing Partnership depending on portfolio shape.
Tel Aviv cyber, AI/ML, medtech, biotech, autonomous, and infrastructure owners working into US enterprise commercialisation.
See the Tel Aviv gate →Tel Aviv founder-operator and venture-studio owners into US enterprise commercialisation. Cyber, AI/ML, infrastructure, medtech.
See the Tel Aviv operators sub →London cyber, fintech, medtech, and capital-adjacent owners working into US enterprise and US health-system commercialisation.
See the London gate →Dubai family-office, sovereign-adjacent, and DIFC owners working into US enterprise and US infrastructure commercialisation.
See the Dubai gate →The European parallel pattern. DACH Mittelstand industrial and engineer-led firms in front of US procurement, and what the rebuild sequence looks like.
Evaluate the pillar →Market-Entry Marketing Sprint, Cross-Border Marketing Build, Global Marketing Partnership.
See the engagements →If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | Use this page as a decision note, not as general commentary. It should answer one market-entry tension. |
| What may be unclear | The tension is that the company may be strong at home while the new-market buyers evaluate the proof, language, channel, price, or follow-up as weak. |
| What to inspect | The consequence is wasted spend, slower pipeline, distributor drift, weak RFQs, or buyers who like the product but do not move. |
| Next step | Use the example on this page to decide whether the next move is more context, /engagements/, or /contact/#inquiry. |